All posts related to "rheumatoid arthritis"

Call for patient input on tofacitinib (Xeljanz®) for the treatment of rheumatoid arthritis

Do you have rheumatoid arthritis or care for someone who does? We need your valuable input.

Megaphone GraphicThe Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input on the manufacturer’s submission for tofacitinib (Xeljanz®) for the treatment of rheumatoid arthritis (RA). Tofacitinib is an oral disease-modifying anti-rheumatic drug (DMARD) that was issued a Notice of Compliance (NOC) from Health Canada on April 17, 2014. Tofacitinib in combination with methotrexate (MTX), is indicated for reducing the signs and symptoms of RA, in adult patients with moderately to severely active RA who have had an inadequate response to MTX. In cases of intolerance to MTX, physicians may consider the use of tofacitinib as monotherapy.

The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec). 

To help them make their recommendations, the CDR accepts input from patient groups, like Arthritis Consumer Experts (ACE). We would like to gather your views and share them with the CDR.

These are the questions they are asking:

Continue reading

Psoriatic arthritis may increase risk of cardiovascular event

Broken HeartResearch presented at the 2014 European League Against Rheumatism annual congress in Paris, France in June suggests that there is a connection between psoriatic arthritis (PsA) and cardiovascular (CV) risk factors.

Lead investigator, Agnete Malm G. Gulati, MD, said that the main objective of her study is to see whether patients with PsA had more CV risk factors and disease as compared to the controlled group. The study also looked at the 10-year risk for a fatal CV event by using the Systemic Coronary Risk Evaluation (SCORE) measurement. The end result is to compare the estimated risk in patients with PsA and the control group.

SCORE measures CV risk factors such as age, sex, systolic blood pressure, and cholesterol, which were similar between the PsA and controlled group. There were more smokers in the group with PsA. The PsA group also had increased body mass index (BMI), triglyceride level, C-reactive protein level, and elevated diastolic blood pressure – all of which are CV risk factors. There was a higher prevalence rate of angina pectoris and hypertension in the PsA group.

What does this mean for patients?

Continue reading

“Words and Pictures” and rheumatoid arthritis – Now playing at a theatre near you

Rarely, if ever, have the movies depicted rheumatoid arthritis, but last Friday, the movie “Words and Pictures”, starring Academy Award-winning actress Juliette Binoche, did just that.

Words and Pictures tells the story of an artist – Dina Delsanto, Ms. Binoche’s character – who, challenged by advancing rheumatoid arthritis (RA), had to change the way she painted and deal with the emotional challenges brought on by the disease. This is perhaps the first time a feature film has focused attention on rheumatoid arthritis – an autoimmune disease with hallmark symptoms of inflammation and resulting pain.

Arthritis Consumer Experts (ACE) Founder, Cheryl Koehn, was thrilled to be called on to assist Ms. Binoche in her preparation for the role, and honoured to be asked to review the script and provide comment to ensure the emotional characterization of RA was as accurate as film would allow. Kudos go to ACE physiotherapy advisor, Dr. Linda Li, who assisted Ms. Binoche with the physical portrayal of her character, and Mr. Otto Kamensek, an arthritis community leader and artist himself, who shared his artistic process and art.

Congratulations to everyone involved in the making of Words and Pictures and the awareness it will raise for RA.

Early Symptoms of Autoimmune Arthritis: A Patient-Centered Research Study

Equation for EMCEarly Symptoms of Autoimmune Arthritis: A Patient-Centered Research Study

Participate in this study to help develop and maintain a new equation for change in rheumatology

The International Foundation for Autoimmune Arthritis (IFAA), with the help of the Spondylitis Association of America, Lupus UK, Sjögren’s Syndrome Foundation, and the International Still’s Disease Foundation, have created a study called the “Early Symptoms of Autoimmune Arthritis: A Patient-Centered Research Study”.

The purpose of the study is to develop and maintain a new equation for change in rheumatology. According to the research, early detection + early referrals + early diagnosis + early treatment = better chance to combat unnecessary, irreversible damage and elevate the chances for remission in autoimmune arthritis. The study hopes to address improper identification of early symptoms that may correlate with a delay in diagnosis. 
Continue reading

Let BC PharmaCare hear “Your Voice” on golimumab intravenous

Megaphone GraphicLet BC PharmaCare hear “Your Voice” on golimumab intravenous 

BC PharmaCare is looking for your input on the intravenous form of golimumab for the treatment of rheumatoid arthritis

The intravenous (IV) form of golimumab (Simponi® IV) is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide feedback about golimumab IV for the treatment of moderately to severely active rheumatoid arthritis (RA). 
Continue reading

People with rheumatoid arthritis are living longer

Big Ben Clock in United KingdomA researcher in the United Kingdom has reported that the life expectancy for people living with rheumatoid arthritis (RA) has increased over the past 25 years. In an interview with MedPage Today, Sam Norton, PhD, of King’s College in London reports: “The average age at death for RA patients in cohort that enrolled patients between 1986 and 1998 was 76.7 years, while for a cohort that enrolled patients between 2002 and 2012, the average age of death was 86.7.” Continue reading